Expression of WASP and Scar1/WAVE1 actin-associated proteins is differentially modulated during differentiation of HL-60 cells.
The Wiskott-Aldrich Syndrome (WAS) is a disease associated with mutations in the WAS gene and characterised by developmental defects in haematopoietic cells such as myeloid cells. The Wiskott-Aldrich Syndrome protein (WASP)-family includes Scar1 and WASP, which are key regulators of actin reorganization in motile cells. To understand the roles of Scar1 and WASP in myeloid cells and their cytoskeletal control in haematopoietic tissues, we have explored their expression during differentiation of the promyeloid cell line HL-60. Undifferentiated HL-60 cells expressed Scar1 and WASP, and differentiation to neutrophils, induced by retinoic acid or non-retinoid agent treatments, led to a decrease in the level of expression of Scar1, whereas WASP expression was unaffected. Differentiation to monocytes/macrophages, induced by phorbol ester treatment, resulted in a decreased expression of both proteins in the adherent mature cells. Vitamin D(3) treatment or cytochalasin D in combination with PMA treatment did not affect WASP expression suggesting that adhesion and cytoskeletal integrity were both essential to regulate WASP expression. Scar1 expression was regulated by differentiation, adhesion, and cytoskeletal integrity. Recently, WASP was found to colocalize with actin in the podosomes. In contrast, we show here that Scar1 did not localize with the podosomes in mature monocytes/macrophages. These observations show for the first time that modulation of Scar1 and WASP expression is a component of the differentiation program of myeloid precursors and indicate that WASP and Scar1 have different roles in mature myeloid cells.
Launay
Sophie
S
School of Biosciences, University of Birmingham, Edgbaston, Birmingham, United Kingdom.
Brown
Geoffrey
G
Machesky
Laura M
LM
D008841:Actin Cytoskeleton / Q000378:metabolism*; D000818:Animals; D000906:Antibodies; D019556:COS Cells; D002448:Cell Adhesion / Q000187:drug effects / Q000502:physiology; D002454:Cell Differentiation / Q000502:physiology*; D002762:Cholecalciferol / Q000494:pharmacology; D015638:Cytochalasin D / Q000494:pharmacology; D015536:Down-Regulation / Q000502:physiology; D018922:HL-60 Cells; D006801:Humans; D007150:Immunohistochemistry; D008840:Microfilament Proteins / Q000276:immunology / Q000378:metabolism*; D009000:Monocytes / Q000378:metabolism; D022423:Myeloid Cells / Q000166:cytology / Q000378:metabolism*; D023461:Myeloid Progenitor Cells / Q000166:cytology / Q000378:metabolism*; D038042:Myelopoiesis / Q000502:physiology*; D010703:Phorbol Esters / Q000494:pharmacology; D011506:Proteins / Q000378:metabolism*; D014212:Tretinoin / Q000494:pharmacology; D051316:Wiskott-Aldrich Syndrome Protein; D051300:Wiskott-Aldrich Syndrome Protein Family
D000906:Antibodies; D008840:Microfilament Proteins; D010703:Phorbol Esters; D011506:Proteins; C495767:WAS protein, human; D051316:Wiskott-Aldrich Syndrome Protein; D051300:Wiskott-Aldrich Syndrome Protein Family; D002762:Cholecalciferol; D015638:Cytochalasin D; D014212:Tretinoin